menu
    • menu
    [{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SGT-210","moa":"EGFR","graph1":"Dermatology","graph2":"Phase I","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Padagis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Padagis","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Padagis"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tretinoin","moa":"RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Galderma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Jefferies LLC"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Patidegib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Sol-Gel Technologies \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Raymond James & Associates"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"PellePharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Patidegib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Gel","sponsorNew":"Sol-Gel Technologies \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Patidegib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Padagis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Beimei Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"14","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Sol-Gel Technologies

    Menu

    Sol-Gel Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : MagnaPharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sol-Gel Signs Licenses to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

                            Details : The agreement aims for the commercialization of Twyneo (tretinoin/benzoyl peroxide) and Epsolay (benzoyl peroxide) covering the majority of the European countries.

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : MagnaPharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Beimei Pharma

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sol-Gel and Beimei Pharma Announce Asset Purchase Agreement for TWYNEO® in China

                            Details : Beimei purchases and licenses rights to exclusively commercialize Twyneo (tretinoin). It is an approved product indicated for acne vulgaris in adults and pediatric patients 9 years of age and older.

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : $10.0 million

                            May 16, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Beimei Pharma

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Padagis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

                            Details : Zoryve-Generic (roflumilast), PDE4 Inhibitor, small molecule. It is a topical cream indicated for the treatment of plaque psoriasis in patients six years of age and older.

                            Brand Name : Zoryve-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2024

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Padagis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

                            Details : SGT-610 (patidegib) is a topical gel formulated, small molecule, Hedgehog signaling pathway Inhibitor drug, which is being investigated for the treatment of Gorlin syndrome.

                            Brand Name : SGT-610

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2023

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : SEARCHLIGHT PHARMA INC

                            Deal Size : $11.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

                            Details : Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of ros...

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : SEARCHLIGHT PHARMA INC

                            Deal Size : $11.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Raymond James & Associates

                            Deal Size : $12.8 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

                            Details : The Company intends to use the net proceeds from the Offerings to fund the acquisition of SGT-610, the topically-applied patidegib, a new chemical entity hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome.

                            Brand Name : SGT-610

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 27, 2023

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Raymond James & Associates

                            Deal Size : $12.8 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : PellePharm

                            Deal Size : $74.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potentia...

                            Details : SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA.

                            Brand Name : SGT-610

                            Molecule Type : Small molecule

                            Upfront Cash : $4.7 million

                            January 27, 2023

                            Lead Product(s) : Patidegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : PellePharm

                            Deal Size : $74.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Galderma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

                            Details : Approval of EPSOLAY (benzoyl peroxide) is supported by data from Phase 3 trial, which demonstrated reduction in inflammatory lesions of rosacea by nearly 70% by end of both 12-week trials vs. 38-46% with vehicle.

                            Brand Name : Epsolay

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 25, 2022

                            Lead Product(s) : Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Galderma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of...

                            Details : TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sol-Gel Technologies

                            Israel arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aciclovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Padagis

                            Deal Size : $21.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million

                            Details : Under the new Agreement, Sol-Gel has retained collaboration rights to two generic programs acyclovir cream and ivermectin cream related to four generic drug candidates that it believes to have the most value-generating potential.

                            Brand Name : Acyclovir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 04, 2021

                            Lead Product(s) : Aciclovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Padagis

                            Deal Size : $21.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth